

From: [REDACTED]
Sent: mardi 22 janvier 2019 12:32
To: [REDACTED] (SANTE); [REDACTED] (SANTE)
Cc: [REDACTED] (SANTE); [REDACTED]
Subject: RE: Meeting request on EFSA's scientific opinion on PFOS and PFOA
Attachments: Synopsis 3M Legacy PFAS Health Science Research 18Jan2019.pdf;
Supporting files.zip

Dear [REDACTED],

Per your request and our discussion, attached in this email please find:

- 1) One pdf file titled "Synopsis 3M Legacy PFAS Health Science Research 18Jan2019.pdf"
- 2) One zip file titled "supporting files", these are technical publications that are referenced in the synopsis

Our toxicologist, [REDACTED], and our epidemiologist, [REDACTED] prepared this brief synopsis on the topic of PFOA, PFOS, and serum lipid. We think it might be useful to share these documents with EFSA for their ongoing risk assessment work on PFAS and, in particular, as part of a possible review of EFSA's preliminary scientific opinion on PFOA and PFOS that you mention below.

Please let us know if there are any questions. As said, [REDACTED] would be happy to meet with EFSA and discuss these studies in more details with them.

Thank you again for your consideration.

Kind regards, [REDACTED]

3M Science.
Applied to Life.™

[REDACTED] | [REDACTED]
Public Policy & Government Affairs, Europe
3M Europe, Hermeslaan 7 | 1831 Diegem (Brussels) Belgium
Office: [REDACTED] | Mobile: [REDACTED]
[REDACTED] | www.3M.com

From: [REDACTED]
Sent: Thursday 17 January 2019 18:14
To: [REDACTED]
Cc: [REDACTED]
Subject: [EXTERNAL] RE: Meeting request on EFSA's scientific opinion on PFOS and PFOA

Dear [REDACTED],

The conclusions of the EFSA opinion on the risk to human health related to the presence of perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in food will be reviewed in parallel with the finalisation of the EFSA scientific opinion on the risks to human health, related to the

presence in food of perfluoroalkylated substances other than PFOS and PFOA. As no discussions on possible regulatory actions are planned prior to the finalisation of this second opinion and a possible review of the opinion on PFOS and PFOA, a meeting with DG SANTE would not be useful at this stage.

In your e-mail you mention new scientific developments and evidence. Could you please provide us with a list of the studies you refer to, so that EFSA can verify whether they contain new information, in addition to the studies already considered by EFSA.

Kind regards

[REDACTED]

From: [REDACTED]
Sent: Wednesday, January 16, 2019 4:34 PM
To: [REDACTED] (SANTE); [REDACTED] (SANTE)
Subject: Meeting request on EFSA's scientific opinion on PFOS and PFOA

Dear [REDACTED],

I am writing to you on behalf of 3M regarding the recent European Food Safety Authority (EFSA) [scientific opinion](#) on the risk to human health related to the presence of perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in food.

3M very much appreciates and supports EFSA's mandate and all the work the Authority is doing to protect European citizens from food-related health risks.

Following the adoption of the EFSA opinion on PFOS and PFOA in December 2018, we would very much appreciate the opportunity to meet with the European Commission to discuss next steps from a regulatory point of view, as well as how these might take into account some of the latest scientific developments related to effects on cholesterol levels – which are not reflected as far as we are aware in the EFSA opinion.

As you might know, 3M completed a voluntary phase out of manufacture and use of PFOS and PFOA in 2008. We nevertheless remained committed to furthering scientific research of PFOS and PFOA and to working with regulators, scientists and community stakeholders. In addition to funding studies at leading global research institutions, 3M has, over the past three decades, conducted, collaborated on and published hundreds of its own studies on PFAS.

Our toxicologist, [REDACTED], and our epidemiologist, [REDACTED], would be happy to join the meeting to provide an overview of the latest scientific evidence.

Would you be available to meet in February or early March?

Thank you for your consideration.

Sincerely,



Public Policy & Government Affairs, Europe
3M Europe, Hermeslaan 7 | 1831 Diegem (Brussels) Belgium
Office: [REDACTED] | Mobile: [REDACTED]
[REDACTED] | www.3M.com

3M Notice: This communication is from an [EXTERNAL] sender.

If this email looks suspicious, do **NOT** click or open any links or attachments in the email. To report a suspicious email, click on the **Report Phishing – PhishMe** icon in the Outlook ribbon or forward this email using the report email as spam link in the text below.

Click [here](#) to report this email as spam